Effectiveness of PR013 Topical Ophthalmic Drops Compared to Vehicle of PR013 Topical Ophthalmic Drops for the Treatment of Allergic Conjunctivitis Using Conjunctival Allergen Challenge Model (Ora-CAC®)
Phase of Trial: Phase II
Latest Information Update: 12 Mar 2018
At a glance
- Drugs Hypochlorous acid (Primary)
- Indications Allergic conjunctivitis
- Focus Therapeutic Use
- Sponsors Realm Therapeutics
- 12 Mar 2018 Status changed from recruiting to discontinued, According to a Realm Therapeutics media release.
- 15 Feb 2018 According to a Realm Therapeutics media release, study is ahead of schedule with top-line results expected by the end of Q1 2018, rather than in Q2 as previously indicated.
- 12 Dec 2017 Status changed from planning to recruiting, according to a Realm Therapeutics media release.